Base Year
Historical Year
Forecast Year
The neuroendocrine carcinoma market size was valued at USD 2.44 billion in 2024, driven by the rising prevalence of personalised medicine across the major markets. The market is expected to grow at a CAGR of 10.03% during the forecast period of 2025-2034, with the values likely to rise from USD 2.7 billion in 2025 to USD 5.8 billion by 2034.
Neuroendocrine carcinoma, also referred to as neuroendocrine tumour or neoplasm, initiates in specialized cells of the neuroendocrine system. These cells are present throughout the body and possess the traits of nerve cells as well as hormone producing endocrine cells. This tumour can affect any part of the body, including lungs, pancreas, and the GI (gastrointestinal) tract. Symptoms may vary depending upon the tumor location.
As neuroendocrine carcinoma affects the hormone cells of the body, the repercussions range from skin rashes to diarrhoea to low or high blood pressure. In such cases, somatostatin analogues like octreotide and lanreotide are used. Chemotherapy, targeted therapy, peptide receptor radionuclide therapy are other non-pharmacological interventions used to treat the condition and aid in catering to the rising neuroendocrine carcinoma market demand.
With a specific focus on treating liver NET, radioembolization is being applied to slow down the tumour growth and shrink by directly offering radiation to the liver. This is done with the help of small radioactive particles, lodged inside the tumour to inhibit blood flow and emit radiation, damaging the cancer cells.
The neuroendocrine carcinoma market growth is driven by the increasing collaborations in prominent companies to expand their product portfolio and offer improved treatment alternatives to patients. In October 2023, Eli Lilly and Company acquired Point Biopharma Global to develop radioligand therapy for treating gastroenteropancreatic neuroendocrine tumours (GEP-NETs). The acquisition costed around USD 1.4 billion, which is an indicator that the market is experiencing hefty investments to foster innovation.
Market Breakup by Treatment Type
Market Breakup by Indication
Market Breakup by End User
Market Breakup by Region
The United States has dominated the neuroendocrine carcinoma market share, driven by the rising collaborations between research and academic institutions. In June 2023, Stanford University’s Innovative Medicines Accelerator (IMA) and Intonation Research Laboratories (Intonation) collaborated to develop treatments for cancerous neuroendocrine tumors. With a robust healthcare infrastructure, the region is expected to lead the market in the forecast period as well.
Europe is another major market with numerous well-equipped healthcare and research infrastructure to foster new therapies for neuroendocrine carcinoma treatment. Major collaborations amongst healthcare companies are also contributing to the market value.
With continuously improving medical ecosystem, the Asia Pacific region, particularly Japan, is anticipated to experience maximum neuroendocrine carcinoma market growth. To leverage the academic talent and other resources, countries with emerging economies like India, and South Korea are also witnessing an influx of foreign capital. Such investments may boost the market growth significantly in the forecast period.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Indication |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 2.44 billion in 2024, driven by the rising prevalence of personalised medicines across the major markets.
The market is anticipated to grow at a CAGR of 10.03% during the forecast period of 2025-2034, likely to reach a market value of USD 5.8 billion by 2034.
The market demand is driven by increasing application of technically aided therapeutics other than pharmacological interventions.
The current market trend involves rising mergers and acquisitions between proficient companies to expand research and innovation possibilities. In October 2023, Eli Lilly and Company acquired Point Biopharma Global to develop radioligand therapy for treating gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
The treatment type can be divided into Somatostatin Analogs (SSAs), Targeted Therapy, and Chemotherapy, among Others.
The indications can be categorized into lungs, pancreas, and gastrointestinal, among others.
The end-users in the market include hospitals and clinics, among others.
The major regions of the market include the United States, Japan, EU-4 and the United Kingdom. EU-4 is segmented into Germany, France, Italy, and Spain.
Key players involved in the market are Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Eli Lilly & Company, F. Hoffmann-La Roche Ltd., Ipsen, Baxter, Novartis AG, Pfizer Inc., Lantheus Holdings, Inc., Tarveda Therapeutics, AVEO Pharmaceuticals, Inc., Advanced Accelerator Applications, BioSynthema Inc., Merck Sharp & Dohme Corp., and Bionano Genomics.
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share